Engimmune Therapeutics, a Swiss biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, has closed a CHF 15.5m seed financing round. The round was led by the investors Pureos Bio-ventures and Novo
Tags :Matthias Staehelin
Alloy Therapeutics, a Boston based biotechnology ecosystem company, has entered into a definitive agreement to acquire deepCDR Biologics, a privately held Basel based developer of deep learning technology for antibody discovery and optimisation. Alloy will
Vifor Pharma acquires the Swiss firm Inositec, a clinical stage biopharmaceutical company which is developing first-in-class treatments for unmet medical need. Through this acquisitions, Vifor Pharma will be spearheading the vascular calcification field to improve
GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round. GlycoEra’s
MiniNaviDent has received an investment by Straumann Holding to further develop and market its Denacam system, a miniaturized dynamic navigation system for dental implants. With the investment, Straumann obtained a 39% stake of mininavident. The two
Bachem Holding, an innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides, has raised CHF 583.5 million through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential